These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 25481195)

  • 1. PET scans as a predictive marker of survival in advanced colorectal cancer.
    Choi M; Kollepara SL; Heilbrun LK; Smith D; Shields AF; Philip PA
    Clin Colorectal Cancer; 2015 Mar; 14(1):35-40. PubMed ID: 25481195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contribution of "complete response to treatment" to survival in patients with unresectable metastatic colorectal cancer: A retrospective analysis.
    Bulut G; Guner Oytun M; Almuradova E; Harman M; Uslu R; Karabulut B
    PLoS One; 2021; 16(11):e0259622. PubMed ID: 34748587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of mucin production on survival in colorectal cancer: a case-control study.
    Farhat MH; Barada KA; Tawil AN; Itani DM; Hatoum HA; Shamseddine AI
    World J Gastroenterol; 2008 Dec; 14(45):6981-5. PubMed ID: 19058335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of the evolution of systemic chemotherapy in the management of colorectal cancer.
    Gustavsson B; Carlsson G; Machover D; Petrelli N; Roth A; Schmoll HJ; Tveit KM; Gibson F
    Clin Colorectal Cancer; 2015 Mar; 14(1):1-10. PubMed ID: 25579803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selection of biologics for patients with metastatic colorectal cancer: the role of predictive markers.
    Kasi PM; Hubbard JM; Grothey A
    Expert Rev Gastroenterol Hepatol; 2015 Mar; 9(3):273-6. PubMed ID: 25579664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maintenance monotherapy with gemcitabine after standard platinum-based chemotherapy in patients with advanced urothelial cancer.
    Muto S; Abe H; Noguchi T; Sugiura S; Kitamura K; Isotani S; Ide H; Yamaguchi R; Kamai T; Horie S
    Int J Urol; 2015 May; 22(5):490-4. PubMed ID: 25728995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, RAS-BRAF wild-type colorectal cancer receiving cetuximab or panitumumab.
    Musella V; Pietrantonio F; Di Buduo E; Iacovelli R; Martinetti A; Sottotetti E; Bossi I; Maggi C; Di Bartolomeo M; de Braud F; Daidone MG; Cappelletti V
    Int J Cancer; 2015 Sep; 137(6):1467-74. PubMed ID: 25704501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The neoadjuvant treatment of rectal cancer: a review.
    Nussbaum N; Altomare I
    Curr Oncol Rep; 2015 Mar; 17(3):434. PubMed ID: 25691086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.
    Van Cutsem E; Lenz HJ; Köhne CH; Heinemann V; Tejpar S; Melezínek I; Beier F; Stroh C; Rougier P; van Krieken JH; Ciardiello F
    J Clin Oncol; 2015 Mar; 33(7):692-700. PubMed ID: 25605843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.
    Tabernero J; Yoshino T; Cohn AL; Obermannova R; Bodoky G; Garcia-Carbonero R; Ciuleanu TE; Portnoy DC; Van Cutsem E; Grothey A; Prausová J; Garcia-Alfonso P; Yamazaki K; Clingan PR; Lonardi S; Kim TW; Simms L; Chang SC; Nasroulah F;
    Lancet Oncol; 2015 May; 16(5):499-508. PubMed ID: 25877855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes with bevacizumab-containing and non-bevacizumab-containing regimens in patients with recurrent glioblastoma from US community practices.
    Chen C; Ravelo A; Yu E; Dhanda R; Schnadig I
    J Neurooncol; 2015 May; 122(3):595-605. PubMed ID: 25773061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes of TCR repertoire diversity in colorectal cancer after Erbitux (cetuximab) in combination with chemotherapy.
    Luo W; He WT; Wen Q; Chen S; Wu J; Chen XP; Ma L
    Am J Cancer Res; 2014; 4(6):924-33. PubMed ID: 25520880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multi-center randomized phase II clinical study of bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for Chinese patients with metastatic colorectal cancer.
    Cao R; Zhang S; Ma D; Hu L
    Med Oncol; 2015 Jan; 32(1):325. PubMed ID: 25481673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of oxaliplatin-based chemotherapy + bevacizumab as first-line treatment for advanced colorectal cancer: a systematic review and pooled analysis of published trials.
    Petrelli F; Coinu A; Ghilardi M; Cabiddu M; Zaniboni A; Barni S
    Am J Clin Oncol; 2015 Apr; 38(2):227-33. PubMed ID: 25806713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of age and medical comorbidity on adjuvant treatment outcomes for stage III colon cancer: a pooled analysis of individual patient data from four randomized, controlled trials.
    Haller DG; O'Connell MJ; Cartwright TH; Twelves CJ; McKenna EF; Sun W; Saif MW; Lee S; Yothers G; Schmoll HJ
    Ann Oncol; 2015 Apr; 26(4):715-724. PubMed ID: 25595934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
    Simkens LH; van Tinteren H; May A; ten Tije AJ; Creemers GJ; Loosveld OJ; de Jongh FE; Erdkamp FL; Erjavec Z; van der Torren AM; Tol J; Braun HJ; Nieboer P; van der Hoeven JJ; Haasjes JG; Jansen RL; Wals J; Cats A; Derleyn VA; Honkoop AH; Mol L; Punt CJ; Koopman M
    Lancet; 2015 May; 385(9980):1843-52. PubMed ID: 25862517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switch maintenance treatment with oral vinorelbine and bevacizumab after induction chemotherapy with cisplatin, gemcitabine and bevacizumab in patients with advanced non-squamous non-small cell lung cancer: a phase II study.
    Petrioli R; Francini E; Fiaschi AI; Laera L; Luzzi L; Paladini P; Ghiribelli C; Voltolini L; Bianco V; Roviello G
    Med Oncol; 2015 Apr; 32(4):134. PubMed ID: 25796503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective cardiac surveillance in patients with gynecologic cancer undergoing treatment with pegylated liposomal doxorubicin (PLD).
    Kushnir CL; Angarita AM; Havrilesky LJ; Thompson S; Spahlinger D; Sinno AK; Tanner EJ; Secord AA; Roche KL; Stone RL; Fader AN
    Gynecol Oncol; 2015 Jun; 137(3):503-7. PubMed ID: 25735254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early prediction by 18F-FDG PET/CT for progression-free survival and overall survival in patients with metastatic colorectal cancer receiving third-line cetuximab-based therapy.
    Liu FY; Yen TC; Wang JY; Yang TS
    Clin Nucl Med; 2015 Mar; 40(3):200-5. PubMed ID: 25608159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating endothelial cells and their subpopulations: role as predictive biomarkers in antiangiogenic therapy for colorectal cancer.
    Manzoni M; Comolli G; Torchio M; Mazzini G; Danova M
    Clin Colorectal Cancer; 2015 Mar; 14(1):11-7. PubMed ID: 25591800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.